TriSalus Life Sciences, Inc. (TLSI), Thursday announced 44 percent increase in preliminary fourth-quarter revenue to around $8.3 million, than the last year.
The company noted that the revenue growth was driven solely by the TriNav Infusion System, an innovative solution designed to overcome infusion barriers within solid tumors.
Meanwhile, TriSalus anticipates revenue of about $29.4 million for the fiscal year 2024, representing a year-over-year increase of nearly 59 percent.
The medical technology company further expects the revenue growth to rise by over 50 percent in the full year 2025, which is in consistence with the previously estimated outlook.
Currently, TriSalus's stock is climbing 2.04 percent, to $5 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.